Skip to main content
  • Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease

    • Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery
    • With Portico approval, Abbott offers the industry's most comprehensive portfolio of structural heart solutions in the U.S.

    ABBOTT PARK, Ill., September 20, 2021 — Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Portico™ with FlexNav™ transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. With this latest TAVR (also referred to as TAVI, or transcatheter aortic valve implantation) advancement, Abbott continues to offer the industry's leading portfolio of structural heart solutions that include innovative, minimally invasive therapies to repair or replace diseased or damaged heart valves or close openings in the heart.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details